Free Trial
ASX:BOT

Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis

Botanix Pharmaceuticals logo

About Botanix Pharmaceuticals Stock (ASX:BOT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
N/A
Market Capitalization
$912.82 million
P/E Ratio
N/A
Dividend Yield
2.96%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.

Receive BOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BOT Stock News Headlines

Buffett’s $325 Billion Cash Problem — Solved by Gold?
A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.
See More Headlines

BOT Stock Analysis - Frequently Asked Questions

Botanix Pharmaceuticals Limited (ASX:BOT) posted its quarterly earnings data on Thursday, February, 28th. The company reported ($0.01) EPS for the quarter. Botanix Pharmaceuticals had a negative net margin of 670.20% and a negative trailing twelve-month return on equity of 18.00%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB).

Company Calendar

Last Earnings
2/28/2019
Today
5/30/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:BOT
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.87 million
Net Margins
-670.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.07 million
Price / Cash Flow
1.50
Book Value
A$0.07 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,810,000,000
Free Float
N/A
Market Cap
$912.82 million
Optionable
Not Optionable
Beta
1.71
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:BOT) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners